An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Active:	Yes
Cancer Type:	Melanoma	NCT ID:	NCT03897881
Trial Phases:	Phase II	Protocol IDs:	mRNA-4157-P201 (primary) NCI-2019-04957
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	ModernaTX, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03897881

Summary

The purpose of this study is to assess whether postoperative adjuvant therapy with
mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to
pembrolizumab alone in participants with complete resection of cutaneous melanoma and a
high risk of recurrence.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.